Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study)

What Was Tested

This randomized controlled trial paper looks at Semaglutide.

To assess whether oral semaglutide provides better glycaemic control, compared with dipeptidyl peptidase-4 inhibitor (DPP-4i) continuation, in people with type 2 diabetes.

How the Study Was Run

The design is described as randomized, open-label, multicenter and parallel-group.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Semaglutide study did not mask who received what.

More than one site took part, so the participants came from several places.

Groups ran in parallel: each of the participants stayed in one arm throughout.

The methods mention a period of 24 weeks.

The primary endpoint was the change in glycated haemoglobin (HbA1c) over 24 weeks.

Secondary endpoints included changes in metabolic parameters and biomarkers, along with the occurrence of adverse events.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Glycated Hemoglobin, Glycemic Control, Hypoglycemic Agents, Glucagon-Like Peptides and Dipeptidyl-Peptidases and Tripeptidyl-Peptidases.

The authors tagged it with the keywords DPP-IV inhibitor, GLP-1 analogue, clinical trial, glycaemic control, randomized trial and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Semaglutide over 24 weeks.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page, all human trials.